Immuron Ltd ADR (IMRN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.21 (+2.54%), Market cap $0.01B, 52-week low–high $0.70 ~ $2.35.
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and
Financial statements, price targets, institutional (13F) holdings and related news for Immuron Ltd ADR are updated in real time on BlackAll Trade.
Immuron Ltd ADR trades at $1.21 (+2.54%). Real-time quotes and charts are available on BlackAll Trade.
Immuron Ltd ADR has a market cap of about $0.01B.
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two